The solubility ceiling: A rationale for continuous infusion amphotericin B therapy? [9]

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 871-872

  Lewis, Russell E ^a   Wiederhold, Nathan P ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ASPERGILLUS; BINDING SITE; BIOASSAY; CANDIDA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INFUSION; FUNGICIDAL ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; ULTRAFILTRATION;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; DEOXYCHOLIC ACID; HUMANS; MYCOSES; NEUTROPENIA; SOLUBILITY;

EID: 0141453164     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377279     Document Type: Letter

References (12)

1. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36:943-51.
2. Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002; 132:455-8.
3. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322:579-82.
4. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47:1179-86.
5. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimlcrob Agents Chemother 2001; 45:922-6.
6. Hiemenz JW. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference? Clin Infect Dis 2003; 36:952-3.
7. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41:1392-5.
8. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46:834-40.
9. Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985; 152:1037-43.
10. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989; 33:362-8.
11. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13:271-6.
12. Chabot GG, Pazdur R, Valeriote FA, Baker LH. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci 1989; 78:307-10.